Rimonabant attenuates amphetamine sensitisation in a CCK2 receptor-dependent manner

Behavioural Brain Research

Volumn 226, Issue 1, 2012, Pages 335-339

  Rünkorg, Kertu ^a   Orav, Laura ^a   Kõks, Sulev ^a   Matsui, Toshimitsu ^a,b   Volke, Vallo ^a   Vasar, Eero ^a  

^a UNIVERSITY OF TARTU   (Estonia)

^b KOBE UNIVERSITY   (Japan)

Author keywords

Amphetamine; CB1 receptors; CCK2 receptors; Knockout mice; Motor sensitisation; Rimonabant

Indexed keywords

AMPHETAMINE; CANNABINOID 1 RECEPTOR; CHOLECYSTOKININ B RECEPTOR; RIMONABANT;

ANALGESIA; ANIMAL EXPERIMENT; ANXIETY; ARTICLE; AVERSION; CHEMICAL ANALYSIS; CONDITIONING; CONTROLLED STUDY; MALE; MOTOR ACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SENSITIZATION;

AMPHETAMINE; ANIMALS; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM STIMULANTS; ENDOCANNABINOIDS; MALE; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; PIPERIDINES; PYRAZOLES; RECEPTOR, CHOLECYSTOKININ B; RECEPTORS, CANNABINOID;

EID: 80054843051     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2011.09.005     Document Type: Article

References (23)

1. Noble F., Wank S.A., Crawley J.N., et al. International Union of Pharmacology, XXI. Structure, distribution, and functions of cholecystokinin receptors. Pharmacol Rev 1999, 51:745-781.
2. van der Stelt M., Di Marzo V. The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur J Pharmacol 2003, 480:133-150.
3. Marsicano G., Lutz B. Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci 1999, 11:4213-4225.
4. Beinfeld M.C., Connolly K. Activation of CB1 cannabinoid receptors in rat hippocampal slices inhibits potassium-evoked cholecystokinin release, a possible mechanism contributing to the spatial memory defects produced by cannabinoids. Neurosci Lett 2001, 301:69-71.
5. Kurrikoff K., Inno J., Matsui T., et al. Stress-induced analgesia in mice: evidence for interaction between endocannabinoids and cholecystokinin. Eur J Neurosci 2008, 27:2147-2155.
6. Nagata A., Ito M., Iwata N., et al. G protein-coupled cholecystokinin-B/gastrin receptors are responsible for physiological cell growth of the stomach mucosa in vivo. Proc Natl Acad Sci USA 1996, 93:11825-11830.
7. Koks S., Volke V., Veraksits A., et al. Cholecystokinin 2 receptor-deficient mice display altered function of brain dopaminergic system. Psychopharmacology 2001, 158:198-204.
8. Runkorg K., Veraksits A., Kurrikoff K., et al. Distinct changes in the behavioural effects of morphine and naloxone in CCK2 receptor-deficient mice. Behav Brain Res 2003, 144:125-135.
9. Tirelli E., Laviola G., Adriani W. Ontogenesis of behavioral sensitization and conditioned place preference induced by psychostimulants in laboratory rodents. Neurosci Biobehav Rev 2003, 27:163-178.
10. Featherstone R.E., Kapur S., Fletcher P.J. The amphetamine-induced sensitized state as a model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:1556-1571.
11. Tzavara E.T., Degroot A., Wade M.R., et al. CB1 receptor knockout mice are hyporesponsive to the behavior-stimulating actions of d-amphetamine: role of mGlu5 receptors. Eur Neuropsychopharmacol 2009, 19:196-204.
12. Thiemann G., van der Stelt M., Petrosino S., et al. The role of the CB1 cannabinoid receptor and its endogenous ligands, anandamide and 2-arachidonoylglycerol, in amphetamine-induced behavioural sensitization. Behav Brain Res 2008, 187:289-296.
13. Compton D.R., Aceto M.D., Lowe J., et al. In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther 1996, 277:586-594.
14. Ben-Shahar O., Ettenberg A. Repeated stimulation of the ventral tegmental area sensitizes the hyperlocomotor response to amphetamine. Pharmacol Biochem Behav 1994, 48:1005-1009.
15. Koks S., Volke V., Veraksits A., et al. Cholecystokinin2 receptor-deficient mice display altered function of brain dopaminergic system. Psychopharmacology (Berl) 2001, 158:198-204.
16. Runkorg K., Varv S., Matsui T., et al. Differences in behavioural effects of amphetamine and dopamine-related gene expression in wild-type and homozygous CCK2 receptor deficient mice. Neurosci Lett 2006, 406:17-22.
17. Rasmussen K., Czachura J.F., Stockton M.E., et al. Electrophysiological effects of diphenylpyrazolidinone cholecystokinin-B and cholecystokinin-A antagonists on midbrain dopamine neurons. J Pharmacol Exp Ther 1993, 264:480-488.
18. Harro J., Vasar E. Evidence that CCKB receptors mediate the regulation of exploratory behaviour in the rat. Eur J Pharmacol 1991, 193:379-381.
19. Raud S., Innos J., Abramov U., et al. Targeted invalidation of CCK2 receptor gene induces anxiolytic-like action in light-dark exploration, but not in fear conditioning test. Psychopharmacology (Berl) 2005, 181:347-357.
20. Moreira F.A., Kaiser N., Monory K., et al. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. Neuropharmacology 2008, 54:141-150.
21. Haller J., Varga B., Ledent C., et al. CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents. Behav Pharmacol 2004, 15:299-304.
22. Griebel G., Stemmelin J., Scatton B. Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol Psychiatry 2005, 57:261-267.
23. Patel S., Hillard C.J. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther 2006, 318:304-311.